The direct cost of epilepsy in the United States: A systematic review of estimates

Epilepsia

Volumn 56, Issue 9, 2015, Pages 1376-1387

  Begley, Charles E ^a   Durgin, Tracy L ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

Burden of illness; Cost; Cost of illness; Costs and cost analysis; Economic burden; Economics; Epilepsy; Seizures

Indexed keywords

GABAPENTIN; PREGABALIN;

ANTICONVULSANT THERAPY; ATTRIBUTABLE RISK; BIBLIOGRAPHIC DATABASE; COMORBIDITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA EXTRACTION; DRUG RESISTANT EPILEPSY; EMBASE; EPILEPSY; HEALTH CARE COST; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MEDICAID; MEDICAL CARE; MEDICAL INFORMATION; MEDLINE; META ANALYSIS; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; POPULATION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SEIZURE; SPEECH THERAPY; STUDY DESIGN; SYSTEMATIC REVIEW; UNITED STATES; ECONOMICS; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; EPILEPSY; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 84940952289     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13084     Document Type: Review

References (42)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al., How common are the "common" neurologic disorders? Neurology 2007; 68: 326-337.
2. Institute of Medicine (IOM). Epilepsy across the spectrum: promoting health and understanding. Washington, DC: The National Academies Press; 2012.
3. Koh HK, Kobau R, Whittemore VH, et al., Toward an integrated public health approach for epilepsy in the 21st century. Prev Chronic Dis 2014; 11: 140270.
4. Forsgren L, Hauser WA, Olafsson E, et al., Mortality of epilepsy in developed countries: a review. Epilepsia 2005; 46 (Suppl. 11): 18-27.
5. Kobau R, Zahran H, Thurman DJ, et al., Epilepsy surveillance among adults-19 states, behavioral risk factor surveillance system, 2005. MMWR Surveill Summ 2008; 57: 1-20.
6. Centers for Disease Control and Prevention (CDC). Epilepsy in adults and access to care-United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 909-913.
7. Yoon D, Frick KD, Carr DA, et al., Economic impact of epilepsy in the United States. Epilepsia 2009; 50: 2186-2191.
8. Begley CE, Famulari M, Annegers JF, et al., The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41: 342-351.
9. Strzelczyk A, Reese JP, Dodel R, et al., Cost of epilepsy: a systematic review. Pharmacoeconomics 2008; 26: 463-476.
10. Pugliatti M, Beghi E, Forsgren L, et al., Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007; 48: 2224-2233.
11. Moher D, Liberati A, Tetzlaff J, et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
12. Cramer JA, Wang ZJ, Chang E, et al., Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy Behav 2014; 31: 356-362.
13. Cramer JA, Wang ZJ, Chang E, et al., Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy Behav 2014; 32: 135-141.
14. Wilner AN, Sharma BK, Thompson A, et al., Diagnoses, procedures, drug utilization, comorbidities, and cost of health care for people with epilepsy in 2012. Epilepsy Behav 2014; 41: 83-90.
15. United States Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available at: http://www.bls.gov/cpi/. Accessed June 5, 2014.
16. Begley CE, Lairson DR, Reynolds TF, et al., Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 2001; 47: 205-215.
17. Burke TA, McKee JR, Pathak DS, et al., Costs of epilepsy in an intermediate care facility for persons with mental retardation. Am J Ment Retard 1999; 104: 148-157.
18. Chen SY, Wu N, Boulanger L, et al., Antiepileptic drug treatment patterns and economic burden of commercially-insured patients with refractory epilepsy with partial onset seizures in the United States. J Med Econ 2013; 16: 240-248.
19. Davis KL, Candrilli SD, Edin HM,. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008; 49: 446-454.
20. Ettinger AB, Manjunath R, Candrilli SD, et al., Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009; 14: 324-329.
21. Faught RE, Weiner JR, Guérin A, et al., Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia 2009; 50: 501-509.
22. Frost FJ, Hurley JS, Petersen HV, et al., A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000; 41: 1020-1026.
23. Gardner EN, Murtaugh CM, Ray NF, et al., The cost of Medicaid-covered services provided to disabled adults with neurologic disorders: implications for managed care. Am J Manag Care 1999; 5: 1417-1425.
24. Griffiths RI, Schrammel PN, Morris GL, et al., Payer costs of patients diagnosed with epilepsy. Epilepsia 1999; 40: 351-358.
25. Ivanova JI, Birnbaum HG, Kidolezi Y, et al., Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010; 28: 675-685.
26. Ivanova JI, Birnbaum HG, Kidolezi Y, et al., Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010; 51: 838-844.
27. Kleinman NL, Sadosky A, Seid J, et al., Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. Epilepsy Res 2012; 102: 13-22.
28. Lee WC, Arcona S, Thomas SK, et al., Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder. Epilepsy Behav 2005; 7: 123-126.
29. Libby AM, Ghushchyan V, McQueen RB, et al., Economic differences in direct and indirect costs between people with epilepsy and without epilepsy. Med Care 2012; 50: 928-933.
30. Manjunath R, Paradis PE, Parisé H, et al., Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology 2012; 79: 1908-1916.
31. Penberthy LT, Towne A, Garnett LK, et al., Estimating the economic burden of status epilepticus to the health care system. Seizure 2005; 14: 46-51.
32. Vivas AC, Baaj AA, Benbadis SR, et al., The health care burden of patients with epilepsy in the United States: an analysis of a nationwide database over 15 years. Neurosurg Focus 2012; 32: E1.
33. Wilner AN, Sharma BK, Soucy A, et al., Health plan paid cost of epilepsy in 2009 in the US. Epilepsy Behav 2012; 25: 412-416.
34. Zachry WM III, Doan QD, Smith BJ, et al., Direct medical costs for patients seeking emergency care for losses of epilepsy control in a US managed care setting. Epilepsy Behav 2009; 16: 268-273.
35. Holden EW, Grossman E, Nguyen HT, et al., Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag 2005; 8: 1-14.
36. Thurman DJ, Beghi E, Begley CE, et al., Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011; 52 (Suppl. 7): 2-26.
37. Reid AY, St Germaine-Smith C, Liu M, et al., Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res 2012; 102: 173-179.
38. Kee VR, Gilchrist B, Granner MA, et al., A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl. 1): 183-193.
39. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al., Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology 2012; 79: 1049-1055.
40. Murray MI, Halpern MT, Leppik IE,. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996; 23: 139-148.
41. Halpern M, Rentz A, Murray M,. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000; 19: 87-99.
42. Begley CE, Annegers JF, Lairson DR, et al., Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-1243.